Register for free to listen to this article
Listen with Speechify
0:00
1:00
JACKSON, Miss.—Eli Lilly & Co. will pay $18.5 million toend Mississippi's case against it for promotional claims related to theanti-psychotic drug Zyprexa, according to an announcement made by stateAttorney General Jim Hood at the end of January. Under the settlement, Lillyagreed to curb marketing activities and payments to healthcare professionalsfor non-approved uses Zyprexa, which is approved for the treatment of bipolardisorders. Lilly had been accused of promoting the drug for any kind ofdepression. In the 23-page settlement, Lilly did not admit that it violated anystate consumer protection laws and said it had not committed any "liability,fault or wrongdoing." The agreement with the Attorney General's Office does notprotect Lilly from criminal allegations.

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue